Biotechnology Analyst Zelin discusses chronic graft vs host disease and the opportunity for Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Axatilimab on an Analyst/Industry conference call to be held on June 28 at 2 pm. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNDX:
- 3 Best Stocks to Buy Now, 6/26/2023, According to Top Analysts
- BTIG keeps Buy on Syndax, raises price target to $35
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
- SNDX Earnings this Week: How Will it Perform?